Inclusion Criteria:

- Aged at least 20 years

- Histological or cytological confirmation of a solid malignant tumour, excluding
lymphoma, that is refractory to standard therapies or for which no standard therapies
exist

- At least one lesion (measurable and/or non-measurable) that can be accurately
assessed according to RECIST

- World Health Organisation (WHO) performance status 0-1 with no deterioration over the
previous 2 weeks and minimum life expectancy of 12 weeks

- Patients should be willing to remain in hospital until the completion of the first
cycle including cycle 0, cycle 1, and cycle 2 Day1 (as cycle 1 Day 21)

Exclusion Criteria:

- Clinically significant abnormalities of glucose metabolism as defined by any of the
following:

- Diagnosis of diabetes mellitus type I or II (irrespective of management)

- Baseline fasting glucose value of ≥7 mmol/l (126mg/dL)

- Glycosylated haemoglobin (HbA1C) >6.5%

- Spinal cord compression or brain metastases unless asymptomatic, treated and stable
and not requiring steroids for at least 4 weeks prior to start of study treatment

- Inadequate bone marrow reserve or organ function

- Any evidence of severe or uncontrolled systemic diseases, including active bleeding
diatheses, or active infection

- With the exception of alopecia, any unresolved toxicities from prior therapy greater
than CTCAE grade 1 at the time of starting study treatment